The Effectiveness of the Cabergoline on Preventing the Progression of Prediabetes and Controlling the Insulin Resistance

  • سال انتشار: 1398
  • محل انتشار: دومین کنگره اروپایی آسیایی فارماکواپیدمیولوژی
  • کد COI اختصاصی: AECPMED02_017
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 557
دانلود فایل این مقاله

نویسندگان

Hadi Esmaily

Dept. of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences

Mohammad Abbasi Nazari

Dept. of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences

Faezehsadat Feizabadi

Dept. of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences

چکیده

Introduction: Considering the more prolonged effect of the cabergoline in contrast to bromocriptine along with low complications and also the significance of the central pathway of the glucose metabolism, the high prevalence of obesity and having the metabolic syndrome, it was concluded to estimate the cabergoline effectiveness on preventing the progression of the prediabetes to the type II diabetes. Methods: Two-arm parallel randomized clinical trial was conducted with eighty patients. Patients were treated with the cabergoline for 16 weeks. In the first four weeks, patients received 0.25 mg oral cabergoline twice a week before sleeping, and after that, the cabergoline dosage was increased to 0.5 mg twice a week, and this dosage was continued for 12 weeks. Results and Discussion: cabergoline could significantly reduce the values of Fasting Plasma Glucose (FPG), and 2 h Plasma Glucose (2h-PG) in Oral Glucose Tolerance Tests (OGTT), Hemoglobin A1c (Hb-A1c), Cholesterol, low-density lipoproteins (LDL), 2h-Insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), Insulin Sensitivity Indices (ISI) Cederholm, ISI Matsuda, and Quantitative Insulin-sensitivity Check Index (QUICKI) tests (p< 0.05). Cabergoline did not have any significant effects on the anthropometric parameters including weight, BMI and waist circumference and also, other parameters including Fasting Insulin, High-density lipoproteins (HDL), Atherogenic Factor (LDL / HDL) and Homeostatic Model Assessment of β-cell function (HOMA-β) compared to placebo(p> 0.05). In some of these cases, such as HDL, Fasting Insulin and Atherogenic Factor, the trend of the changes is in favor of the curative effects of cabergoline on the mentioned parameters (p< 0.05). Conclusion: Cabergoline can improve the biochemical factors of the glucose metabolism, and in some other parameters despite having no significant change, it prevented the exacerbation of the disease and led the trend parameter in favor of correcting that parameter.

کلیدواژه ها

Cabergoline, Prediabetes, Glucose metabolism, Fasting Plasma Glucose

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.